0.10
+0.0065(+6.91%)
Currency In EUR
Sector
Healthcare
Industry
Biotechnology
Employees
68
First IPO Date
September 19, 2014
| Name | Title | Pay | Year Born |
| Dr. Jérôme Bailly Pharm.D. | Deputy Chief Executive Officer, Deputy GM, Chief Quality Officer & Qualified Person | 257,789 | 1979 |
| Mr. Thibaut du Fayet | Chief Executive Officer | 355,471 | 1968 |
| Dr. Pascal Birman M.D. | Chief Medical Officer | 0 | N/A |
| Dr. Philip L. Lorenzi M.D., Ph.D. | Consultant & Member of Scientific Board | 0 | N/A |
| Prof. Eric Raymond M.D., Ph.D. | Consultant & Member of Scientific Board | 0 | N/A |
| Mr. Frédéric Mathat | Chief Financial Officer | 0 | N/A |
| Ms. Cindy Fevre | Chief Scientific Officer | 0 | N/A |
| Naomi Eichenbaum | Director Investor Relations | 0 | N/A |
| Prof. Arthur E. Frankel M.D., Ph.D. | Consultant & Member of Scientific Board | 0 | N/A |
| Dr. Bridget Bax Ph.D. | Consultant & Member of Scientific Board | 0 | N/A |
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.
